By: Kevin Grogan
Executive Summary The UK firm is weighing up its options for late-stage development of LEVI-04 after unveiling positive Phase II results of Phase II for the neurotrophin-3 inhibitor in moderate-to-severe osteoarthritis.
Kevin Grogan is the Managing Editor for Europe at Commercial, a publication associated with Informa. With a focus on the pharmaceutical industry, Kevin's articles cover topics such as drug development, clinical trials, partnerships, and market trends. He provides insightful analysis and reporting on the latest developments in the European pharmaceutical landscape.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Kevin Grogan's articles predominantly focus on the healthcare and pharmaceutical industries, specifically covering press releases, private sector announcements, industry-specific news, and government announcements. His coverage also includes scientific topics related to drug development and biotech sectors.
Given this focus, Kevin is likely to be interested in receiving pitches that provide insights into new drug developments, clinical trials advancements, or significant healthcare deals. He may particularly appreciate access to exclusive data or expert commentary from industry professionals with insider knowledge of recent developments within the pharmaceutical field.
It's clear that Kevin has a strong interest in both scientific breakthroughs and business-related news within the pharmaceutical and biotech sectors. Therefore, individuals or organizations aiming to reach out should consider offering unique angles on these themes.
This information evolves through artificial intelligence and human feedback. Improve this profile .